715P The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study

Abstract

Surgical resection is the main treatment for hepatocellular carcinoma (HCC) in China. While more than 70% of HCC are in the intermediate or advanced stages at diagnosis and are unresectable; For those patients, transarterial chemoembolization (TACE) is the main conversion therapy to improve the resectability rate and to diminish postoperative relapse. But its success rate is only about 10%; Both Lenvatinib and PD-1 inhibitors (immune checkpoint inhibitors) are indicated for unresectable HCC (uHCC); The purpose of this study was to assess the safety and efficacy of Lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone as conversion therapy for patients with initially uHCC.